Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

[Clinicopathological significance of the expression of calreticulin in human pancreatic cancer].

Sheng WW, Dong M, Zhou JP, Li X, Dong Q.

Zhonghua Wai Ke Za Zhi. 2013 Jan 1;51(1):58-61. Chinese.

PMID:
23578430
2.

[Clinicopathological significance of the expression of carbonic anhydrase I and II in human pancreatic cancer].

Sheng WW, Dong M, Zhou JP, Kong FM, Li YJ.

Zhonghua Yi Xue Za Zhi. 2012 Dec 25;92(48):3407-11. Chinese.

PMID:
23327700
3.

[Clinicopathological significance of the expression of carbonic anhydrase II in human pancreatic invasive ductal cancer].

Sheng WW, Zhou JP, Kong FM, Li YJ, Dong M.

Zhonghua Wai Ke Za Zhi. 2012 Aug;50(8):728-31. Chinese.

PMID:
23157907
4.

[Expression and clinical significance of Tspan 1 and Integrin α6 in human pancreatic ductal adenocarcinoma].

Shi G, Dong M, Sheng W, Zhou J, Yu D, Sun W.

Zhonghua Wai Ke Za Zhi. 2014 Oct;52(10):781-6. Chinese.

PMID:
25573220
5.

[Expression and significance of leukemia inhibitory factor in human pancreatic cancer].

Peng F, Zhou J, Sheng W, Zhang D, Dong M.

Zhonghua Yi Xue Za Zhi. 2014 Jan 14;94(2):90-5. Chinese.

PMID:
24721346
6.

[The relationship and clinicopathological significance of Numb,MDM2 and p53 expression in human pancreatic cancer].

Sheng W, Dong M, Zhou J, Li X, Liu Q, Dong Q, Li F.

Zhonghua Wai Ke Za Zhi. 2014 Sep;52(9):675-81. Chinese.

PMID:
25410780
7.

[Correlation between Gli1 expression and clinicopathological significance in human pancreatic cancer].

Sheng WW, Dong M, Zhou JP, Liu QF, Li X, Dong Q.

Zhonghua Wai Ke Za Zhi. 2013 Oct;51(10):916-21. Chinese.

PMID:
24433772
8.

Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.

Piao J, Liu S, Xu Y, Wang C, Lin Z, Qin Y, Liu S.

Exp Mol Pathol. 2015 Feb;98(1):1-6. doi: 10.1016/j.yexmp.2014.11.003. Epub 2014 Nov 5.

PMID:
25445504
9.

Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma.

Jin A, Xu Y, Liu S, Jin T, Li Z, Jin H, Lin L, Lin Z.

Exp Mol Pathol. 2014 Feb;96(1):54-60. doi: 10.1016/j.yexmp.2013.11.003. Epub 2013 Nov 18.

PMID:
24263054
10.

Claudin-4 expression predicts survival in pancreatic ductal adenocarcinoma.

Tsutsumi K, Sato N, Tanabe R, Mizumoto K, Morimatsu K, Kayashima T, Fujita H, Ohuchida K, Ohtsuka T, Takahata S, Nakamura M, Tanaka M.

Ann Surg Oncol. 2012 Jul;19 Suppl 3:S491-9. doi: 10.1245/s10434-011-1970-2. Epub 2011 Aug 12.

PMID:
21837532
11.

High expression of interleukin-22 and its receptor predicts poor prognosis in pancreatic ductal adenocarcinoma.

Wen Z, Liao Q, Zhao J, Hu Y, You L, Lu Z, Jia C, Wei Y, Zhao Y.

Ann Surg Oncol. 2014 Jan;21(1):125-32. doi: 10.1245/s10434-013-3322-x. Epub 2013 Oct 17.

PMID:
24132627
12.

A comprehensive examination of Smad4, Smad6 and Smad7 mRNA expression in pancreatic ductal adenocarcinoma.

Singh P, Wig JD, Srinivasan R, Radotra BD.

Indian J Cancer. 2011 Apr-Jun;48(2):170-4. doi: 10.4103/0019-509X.82876.

13.

Expression and clinical significance of apolipoprotein E in pancreatic ductal adenocarcinoma.

Chen J, Chen LJ, Yang RB, Xia YL, Zhou HC, Wu W, Lu Y, Hu LW, Zhao Y.

Med Oncol. 2013;30(2):583. doi: 10.1007/s12032-013-0583-y. Epub 2013 Apr 23.

PMID:
23609192
14.

Overexpression of protein phosphatase 4 correlates with poor prognosis in patients with stage II pancreatic ductal adenocarcinoma.

Weng S, Wang H, Chen W, Katz MH, Chatterjee D, Lee JE, Pisters PW, Gomez HF, Abbruzzese JL, Fleming JB, Wang H.

Cancer Epidemiol Biomarkers Prev. 2012 Aug;21(8):1336-43. doi: 10.1158/1055-9965.EPI-12-0223. Epub 2012 Jun 4.

15.

Elevated STMN1 Expression Correlates with Poor Prognosis in Patients with Pancreatic Ductal Adenocarcinoma.

Li J, Hu G, Kong F, Wu K, Song K, He J, Sun W.

Pathol Oncol Res. 2015 Sep;21(4):1013-20. doi: 10.1007/s12253-015-9930-y. Epub 2015 Mar 20.

PMID:
25791566
16.

Levels of HOXB7 and miR-337 in pancreatic ductal adenocarcinoma patients.

Zhang R, Zheng S, Du Y, Wang Y, Zang W, Zhao G.

Diagn Pathol. 2014 Mar 18;9:61. doi: 10.1186/1746-1596-9-61.

17.

Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma.

Yamamoto S, Tomita Y, Hoshida Y, Morooka T, Nagano H, Dono K, Umeshita K, Sakon M, Ishikawa O, Ohigashi H, Nakamori S, Monden M, Aozasa K.

Clin Cancer Res. 2004 Apr 15;10(8):2846-50.

18.

Glypican-3 and KRT19 are markers associating with metastasis and poor prognosis of pancreatic ductal adenocarcinoma.

Yao H, Yang Z, Liu Z, Miao X, Yang L, Li D, Zou Q, Yuan Y.

Cancer Biomark. 2016;17(4):397-404. doi: 10.3233/CBM-160655.

PMID:
27689616
19.

Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression.

Chang DZ, Ma Y, Ji B, Liu Y, Hwu P, Abbruzzese JL, Logsdon C, Wang H.

J Hematol Oncol. 2012 Apr 4;5:15. doi: 10.1186/1756-8722-5-15.

20.

High expression of delta-like ligand 4 predicts poor prognosis after curative resection for pancreatic cancer.

Chen HT, Cai QC, Zheng JM, Man XH, Jiang H, Song B, Jin G, Zhu W, Li ZS.

Ann Surg Oncol. 2012 Jul;19 Suppl 3:S464-74. doi: 10.1245/s10434-011-1968-9. Epub 2011 Aug 6.

PMID:
21822553

Supplemental Content

Support Center